FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation By Ogkologos - October 30, 2025 283 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Niraparib Maintenance Significantly Reduces the Risk of Disease Progression or Death... July 31, 2023 ESMO Congress 2023, 20-24 October 2023 Madrid, Spain October 6, 2023 Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with... December 6, 2024 Perioperative Treatment with Nivolumab Results in Significantly Longer Event-Free Survival than... May 22, 2024 Load more HOT NEWS Survival According Circulating Tumour DNA Status in the Study of Adjuvant... Managing Side Effects with South Asian Foods Elliot Colburn MP: Why Cancer Research UK’s Manifesto for Cancer Research... A Remarkable Group of Patients with Haematological Disorders with No or...
